Overview

A Trial of the Efficacy and Safety Trial of ABY-035 in the Treatment and Prevention of Relapse/Recurrence of Non-anterior Uveitis

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a multinational, multicenter, phase 2 proof-of-concept trial to explore the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant BL disease activity despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).

Phase:

Phase 2

Details

Lead Sponsor:

Affibody

Treatments:

Prednisolone
Prednisone